<DOC>
	<DOCNO>NCT00389051</DOCNO>
	<brief_summary>The purpose study assess tolerability , pharmacokinetics antitumor effect bendamustine hydrochloride ( SyB L-0501 ) patient indolent B-cell Non-Hodgkin 's Lymphoma .</brief_summary>
	<brief_title>A Phase I Study Bendamustine Hydrochloride Patients With Indolent B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Indolent B-cell Non-hodgkin 's lymphoma treat mainly radiation chemotherapy use combination chemotherapy , purine-analogues CHOP ( cyclophosphamide , doxorubicin , vincristine prednisolone ) . After approval antibody therapy agent RituximabÂ® , alone combination CHOP introduce . Bendamustine hydrochloride unique structure compare marketed agent , innovative mechanism action . Thus , expect Bendamustine hydrochloride provide new alternative patient indolent B-cell Non-hodgkin 's lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Indolent B cell NonHodgkin 's lymphoma patient prior therapy satisfy condition list . No restriction regard gender . Patients histologically cytologically confirm indolent B cell NonHodgkin 's lymphoma . Patients receive treatment ( chemotherapy , antibody therapy radiation/ radiotherapy ) 4 week follow prior therapy judge carry effect prior therapy . Patients age 20 less 75 year . Patients agree inpatient first course therapy . Patients write consent participate study obtain . Patients meet follow criterion exclude . Patients apparent infection . Patients serious complication ( hepatic failure renal failure ) . Patients complication history serious heart failure ( e.g . cardiac infarction , ischemic heart disease ) . Patients serious digestive symptom ( nausea/ vomiting/ diarrhea ) . Patients know positive HBV , HCV HIC . Patients receive investigational drug within 3 month registration study . Patients allogenic transplant . Women pregnant , childbearing potential , lactate . Patients agree contraception . Otherwise , patient judge investigator unsuitable inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>Malignant lymphoma</keyword>
</DOC>